These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28173004)

  • 1. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice.
    Ishizu N; Yui D; Hebisawa A; Aizawa H; Cui W; Fujita Y; Hashimoto K; Ajioka I; Mizusawa H; Yokota T; Watase K
    Hum Mol Genet; 2016 Oct; 25(20):4507-4517. PubMed ID: 28173004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease-linked
    Chen X; Kordich JK; Williams ET; Levine N; Cole-Strauss A; Marshall L; Labrie V; Ma J; Lipton JW; Moore DJ
    Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5765-5774. PubMed ID: 30842285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model.
    Chiu CC; Weng YH; Huang YZ; Chen RS; Liu YC; Yeh TH; Lu CS; Lin YW; Chen YJ; Hsu CC; Chiu CH; Wang YT; Chen WS; Liu SY; Wang HL
    Cell Death Dis; 2020 Nov; 11(11):1018. PubMed ID: 33257649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
    Kadgien CA; Kamesh A; Milnerwood AJ
    Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease.
    Niu M; Zhao F; Bondelid K; Siedlak SL; Torres S; Fujioka H; Wang W; Liu J; Zhu X
    Aging Cell; 2021 May; 20(5):e13347. PubMed ID: 33745227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice.
    Vanan S; Zeng X; Chia SY; Varnäs K; Jiang M; Zhang K; Saw WT; Padmanabhan P; Yu WP; Zhou ZD; Halldin C; Gulyás B; Tan EK; Zeng L
    Mol Brain; 2020 Dec; 13(1):164. PubMed ID: 33261640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway.
    Huang Y; Huang H; Zhou L; Li J; Chen X; Thomas J; He X; Guo W; Zeng Y; Low BC; Liang F; Zeng J; Ross CA; Tan EK; Smith W; Pei Z
    Hum Mol Genet; 2022 Nov; 31(22):3886-3896. PubMed ID: 35766879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP.
    Jiang M; Tu HT; Zhang K; Zhang W; Yu WP; Xu J; Tan EK; Guo KH; Zeng L
    Neurobiol Dis; 2021 Jun; 153():105313. PubMed ID: 33636388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin.
    Malik BR; Godena VK; Whitworth AJ
    Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.
    Munsie LN; Milnerwood AJ; Seibler P; Beccano-Kelly DA; Tatarnikov I; Khinda J; Volta M; Kadgien C; Cao LP; Tapia L; Klein C; Farrer MJ
    Hum Mol Genet; 2015 Mar; 24(6):1691-703. PubMed ID: 25416282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
    Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
    Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
    Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
    Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
    Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
    Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contributions of VPS35 Mutations to Parkinson's Disease.
    Rahman AA; Morrison BE
    Neuroscience; 2019 Mar; 401():1-10. PubMed ID: 30660673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation.
    McGough IJ; Steinberg F; Jia D; Barbuti PA; McMillan KJ; Heesom KJ; Whone AL; Caldwell MA; Billadeau DD; Rosen MK; Cullen PJ
    Curr Biol; 2014 Jul; 24(14):1670-1676. PubMed ID: 24980502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D620N mutation in the VPS35 gene and R1205H mutation in the EIF4G1 gene are uncommon in the Greek population.
    Kalinderi K; Bostantjopoulou S; Katsarou Z; Dimikiotou M; Fidani L
    Neurosci Lett; 2015 Oct; 606():113-6. PubMed ID: 26300542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
    Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW
    Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease.
    Chen X; Tsika E; Levine N; Moore DJ
    Mol Neurodegener; 2023 Aug; 18(1):51. PubMed ID: 37542299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of three hiPSC clones from a Parkinson's disease patient with a heterozygous variant of VPS35 p.D620N.
    Ishikawa KI; Ishiguro M; Li Y; Nishioka K; Hattori N; Akamatsu W
    Stem Cell Res; 2022 Apr; 60():102739. PubMed ID: 35247840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.